on-inferiority of Nanodropper-mediated microdrops vs. standard drops of 0.5% timolol maleate in patients with open-angle glaucoma or ocular hypertension - NIND

anodropper Inc0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年2月21日

试验速览

暂无简介。

•1. Patients with a recent diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT) and are not taking any ophthalmic medications for whom 0.5% timolol maleate would be prescribed as a first-line treatment
•2. Participants must have corrected Snellen visual acuity of 6/60 or better in each eye
•3. The baseline IOP should be between 21 and 35 mmHg as assessed by Goldmann applanation tonometry

•1. A recent history (within the past 6 months) of ocular trauma, infection, or uveitis
•2. Baseline IOP of < 21 mmHg
•3. Baseline IOP of > 35 mmHg
•4. History of cardiovascular, pulmonary, cerebrovascular, or chronic renal disease
•5. History of borderline or uncontrolled systemic arterial hypertension
•6. Use of any systemic Î±-agonist or Î²-blocker within 30 days of study commencement
•7. History of receiving general anesthesia within the previous 30 days
•8. Pregnant women and nursing mothers

发起方

anodropper Inc